Improving Public Cancer Care by Implementing Precision Medicine in Norway

Summary

IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.

Conditions

• Cancer Metastatic

Interventions

DRUG

Atezolizumab

drugs used outside indication, based on biomarker

Sponsors & Collaborators

• Haukeland University Hospital

  collaborator OTHER

• St. Olavs Hospital

  collaborator OTHER

• University Hospital of North Norway

  collaborator OTHER

• University Hospital, Akershus

  collaborator OTHER

• Vestre Viken Hospital Trust

  collaborator OTHER

• Hospital of Southern Norway Trust

  collaborator OTHER

• Ostfold Hospital Trust

  collaborator OTHER

• The Hospital of Vestfold

  collaborator OTHER

• Helse Stavanger HF

  collaborator OTHER_GOV

• Nordlandssykehuset HF

  collaborator OTHER

• Sykehuset Innlandet HF

  collaborator OTHER

• Helse Forde

  collaborator OTHER

• Helse Fonna

  collaborator OTHER

• Helse Nord-Trøndelag HF

  collaborator OTHER

• Helse Møre og Romsdal HF

  collaborator OTHER_GOV

• Sykehuset Telemark

  collaborator OTHER_GOV

• Lovisenberg Diakonale Hospital

  collaborator OTHER

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Åslaug Helland, MD PhD · Oslo University Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

16 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2040-03-30

Completion

2045-04-30

Countries

• Norway

Study Locations